Next Article in Journal
Enhanced Antioxidant Capacity and Anti-Ageing Biomarkers after Diet Micronutrient Supplementation
Previous Article in Journal
Challenges and Opportunities of MicroRNAs in Lymphomas
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 19
Issue 9
10.3390/molecules190914782
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model

by
Zhiqin Wu
,
Qingwei Chen
*,
Dazhi Ke
,
Guiqiong Li
and
Wei Deng
Department of Geriatrics, the 2nd Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
*
Author to whom correspondence should be addressed.
Molecules 2014, 19(9), 14782-14793; https://doi.org/10.3390/molecules190914782
Submission received: 17 July 2014 / Revised: 18 August 2014 / Accepted: 1 September 2014 / Published: 17 September 2014
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

Diabetes mellitus (DM) has been recognized as a major health problem. Emodin (Emo) has been reported to exhibit protective effects against diabetic nephropathy. However, little has been known about the effect of Emo on diabetic cardiomyopathy (DCM). A type 2 DM model was induced in rats by low dose streptozotocin (STZ) combined with high energy intake. We found that Emo-treated groups displayed significantly higher body weight (BW) and lower heart weight (HW)/BW. Furthermore, Emo could significantly decrease blood glucose, total cholesterol (TG) levels, and triglyceride (TC) levels in diabetic rats. Moreover, the Emo-treated group showed a marked increase in heart rate (HR) and showed lower left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular posterior wall thickness (LWPWT), and interventricular septal diastolic wall thickness (IVSD). Emo induced a significant increase in phosphorylation of Akt and GSK-3β in myocardium. These results suggest that Emo may have great therapeutic potential in the treatment of DCM by Akt/GSK-3β signaling pathway.
Keywords: emodin; diabetic cardiomyopathy; blood glucose; Akt; GSK-3β emodin; diabetic cardiomyopathy; blood glucose; Akt; GSK-3β

Share and Cite

MDPI and ACS Style

Wu, Z.; Chen, Q.; Ke, D.; Li, G.; Deng, W. Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model. Molecules 2014, 19, 14782-14793. https://doi.org/10.3390/molecules190914782

AMA Style

Wu Z, Chen Q, Ke D, Li G, Deng W. Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model. Molecules. 2014; 19(9):14782-14793. https://doi.org/10.3390/molecules190914782

Chicago/Turabian Style

Wu, Zhiqin, Qingwei Chen, Dazhi Ke, Guiqiong Li, and Wei Deng. 2014. "Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model" Molecules 19, no. 9: 14782-14793. https://doi.org/10.3390/molecules190914782

APA Style

Wu, Z., Chen, Q., Ke, D., Li, G., & Deng, W. (2014). Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model. Molecules, 19(9), 14782-14793. https://doi.org/10.3390/molecules190914782

Article Metrics

Back to TopTop